Although most individuals with insulin-dependent diabetes mellitus (IDDM) have autoantibodies to glutamic acid decarboxylase (GAD), antibodies to GAD are also present in some individuals with a low risk of developing diabetes. The GAD autoantibodies of IDDM are specific for the GAD 65 isoform, do not bind denatured GAD protein, and target epitope(s) dependent on conformation of the protein. However, the IDDM epitopes have been difficult to further define because the antibodies do not bind GAD protein fragments or synthetic peptides. Since the GAD 67 isoform is highly homologous to GAD 65 but is usually not a target of the GAD autoantibodies in IDDM sera, we created six GAD 65 /GAD 67 chimeric proteins to maintain the overall GAD protein conformation and used these chimeric proteins to map conformation-dependent epitopes of GAD 65 targeted by IDDM sera. We find that the GAD binding present in most IDDM sera (n = 11 of 12) is composed of two distinct GAD antibody specificities that target different conformation-dependent regions of the GAD 65 protein, one that is located between amino acids 240 and 435 (termed IDDM-E1) and one that is located between amino acids 451 and 570 (termed IDDM-E2). One IDDM serum (n = 1 of 12) bound only the IDDM-E1 region. Identification of epitopes targeted by IDDM sera may allow one to distinguish between GAD antibody-positive individuals at high and low risk of developing IDDM and to determine if differences in the autoimmune repertoire directed at GAD are present. The chimeric GAD 65 /GAD 67 proteins may also be useful in designing GAD assays specific for IDDM. Diabetes 44: 216-220, 1995 A major autoantigen for both humoral and cellular autoimmunity in insulin-dependent diabetes mellitus (IDDM) is glutamic acid decarboxylase (GAD) (1-3). The possible role of GAD as the primary autoantigen in IDDM has been suggested by recent demonstrations of cellular autoimmunity directed at GAD in IDDM (4,5) and of autoimmunity directed at GAD in an animal model of IDDM (6,7). GAD autoantibodies are an important marker of the autoimmune process of IDDM From the Division of Endocrinology, Department of Medicine (K.D., A.C.P.), Vanderbilt University and the Department of Veterans Affairs Medical Center (A.C.P.), Nashville, Tennessee.
because they are present in the majority of individuals with new-onset diabetes and in individuals in the prediabetic stage of the disease (8) (9) (10) . Improvements and automation of the GAD antibody assay have led to the suggestion that this measurement may be a useful marker to identify individuals at high risk for developing IDDM.
However, GAD autoantibodies are also found in some individuals without IDDM, including individuals with stiffman syndrome (SMS), polyglandular failure type I, or a restricted or p-cell-specific islet cell autoantibody (ICA) pattern (2, (11) (12) (13) . These individuals have a low risk of developing IDDM. Differences and heterogeneity in the GAD autoantibody profile between these nondiabetic individuals and those with IDDM suggest that disease-specific epitopes may exist (13) (14) (15) (16) . For example, SMS sera bind GAD protein fragments and denatured GAD protein used in immunoblotting (1, 14, 15) .
In contrast, GAD antibodies in IDDM do not bind denatured GAD protein, GAD fragments, or GAD peptides, which implies that these GAD antibodies bind an epitope that is dependent on protein conformation (1, 16, 17) . The COOHterminal, two-thirds of the GAD 65 protein, contains the region targeted in IDDM, but when smaller fragments of GAD 65 protein are used, most binding by IDDM sera is lost (16, 17) . Hence, further localization of the IDDM epitopes is not possible with the methodology used to map GAD epitopes targeted by SMS or restricted ICA sera.
We have overcome these experimental limitations in localizing IDDM-related GAD epitopes by designing recombinant GAD proteins that maintain the conformation of the GAD protein. Our experimental approach is based on the following: i ) GAD antibodies in IDDM bind GAD 65 but not GAD 67 (16, 18, 19) ; 2) GAD 65 and GAD 67 are highly homologous in the middle and COOH-terminal regions of the protein (20) ; and 3) GAD 65 and GAD 67 probably have similar protein conformations. By exchanging regions of the GAD 65 and GAD 67 cDNAs, we created chimeric GAD proteins and examined the binding of IDDM antibodies to different regions of the GAD 65 protein.
RESEARCH DESIGN AND METHODS
Creation of GAD 65 /GAD 67 chimeric proteins. To prepare chimeric GAD 65 /GAD 67 cDNAs, a unique restriction enzyme site was introduced into the rat GAD 6B cDNA or human GAD 67 cDNA by polymerase chain reaction (PCR) or site-directed mutagenesis. Introduction of the unique restriction site in the cDNAs did not alter the predicted amino acid sequence and occurred in a stretch of amino acids that were identical in GAD 65 and GAD 67 . PCR amplification was performed using either the human GAD 67 or rat GAD 65 plasmid cDNA and primers to incorporate a 1-, 2-, or 3-base pair mutation. Site-directed mutagenesis was performed with the Transformer Mutagenesis system (Clontech, Palo Alto, CA). The presence of the mutation introduced by PCR or site-directed mutagenesis was confirmed by dideoxy sequencing. After introduction of the desired restriction enzyme site into one GAD isoform, a cDNA fragment was exchanged with the corresponding cDNA fragment from the other GAD cDNA to produce a chimeric cDNA by standard subcloning techniques. For the production of GAD RNA, all wild-type and chimeric GAD cDNAs were subcloned into the plasmid, pGOV, which contains a T7 RNA polymerase promoter (16) .
The following nomenclature for GAD chimera was used: GAD 65 or GAD 67 (amino acid number of that GAD species present in the GAD chimera)/GAD 65 or GAD 67 (amino acid number of that GAD species present in the GAD chimera). The GAD 65 protein has 585 amino acids, and the GAD 67 protein has 594 amino acids. To create the chimera GAD 65 )/GAD 67 (205-594), a Hindi site was introduced at the appropriate location of the GAD 67 cDNA by PCR, and the resulting GAD 67 fragment was exchanged with the corresponding fragment of the GAD 65 cDNA (using a native Hindi site in the GAD 65 cDNA). To create the chimera GAD 67 (l-230)/GAD 65 (221-585), an Afl II was introduced at the appropriate location of the GAD 65 cDNA by PCR, and the resulting GAD 65 fragment was exchanged with the corresponding fragment of the GAD 67 cDNA (using a native Afl II site in the GAD 67 cDNA). To create the chimera GAD 65 (l-442)/GAD 67 (452-594) and the chimera GAD 67 (1- The chimeric composition of the GAD cDNAs was confirmed by restriction enzyme digestion and dideoxy DNA sequencing. After in vitro translation, chimeric proteins were of the expected molecular weight by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. In addition, chimeric proteins containing the COOH-terminus of GAD 65 reacted with the monoclonal antibody GAD-6 (21), which is specific for this region of GAD 66 (16) . The GAD-6 monoclonal antibody was obtained from the Developmental Studies Hybridoma Bank at the University of Iowa (Iowa City, IA; National Institute of Child Health and Human Development contract no. l-HD-2-3144) Serum samples. Serum samples were collected from individuals with new-onset diabetes (n = 12) and from control, nondiabetic individuals and stored at -20°C. The clinical features of the IDDM sera have been previously described (16) . Preparation and immunoprecipitation of GAD protein. Full-length rat GAD 65 , human GAD 67 , and the chimeric GAD 65 /GAD 67 cDNAs were transcribed into GAD RNA using T7 RNA polymerase in an in vitro transcription system (Megascript, Ambion) (16) . Metabolically labeled recombinant GAD protein was prepared by in vitro translation of GAD RNA with reticulocyte lysate (Promega, Madison, WI) using an amino acid mixture containing [ (16) . All dilutions of serum and GAD protein were made with Tris-buffered saline/0.05% Tween 20 (TBST). Protein A-sepharose (PAS, Sigma, St. Louis, MO) was washed and resuspended in TBST to a 2% solution. Two microliters of PAS (final bed volume) was added to the GAD protein/serum reaction and mixed for 1 h at 4°C by gentle rotation. The PAS pellets were then washed three times with 500 ^1 TBST, resuspended in 100 |xl of 1% SDS, and counted by p-scintdllation counting. All serum samples were assayed in duplicate. The results are presented as the means ± SE of at least three separate experiments. Our laboratory participated in the GAD antibody workshops (22) sponsored by the Immunology of Diabetes Workshop (1993 Workshop ( , 1994 . In the 1994 workshop, our GAD 65 assay was positive in 82% of sera from individuals with new-onset diabetes, 100% of sera from individuals with prediabetes, and 3% of normal individuals. (18, 19) (Fig. LA and  B) . Although GAD 65 and GAD 67 differ substantially in the NH 2 -terminal one-third of the protein and the first eight amino acids of GAD 65 are targeted by antibodies in SMS (14, 15) , the GAD 65 -specific autoantibodies in IDDM sera do not bind a chimeric protein consisting of the NH 2 -terminal one-third of GAD 65 and the COOH-terminal two-thirds of GAD 67 [GAD 65 )/GAD 67 (205-594)] (Fig. LA and B) . Conversely, IDDM sera bind the chimera GAD 67 (1-230)/ GAD 65 (221-585) in equivalent amounts as full-length GAD 65 ( Fig. LA and 5 ) . This confirms previous reports that the conformation-dependent epitope targeted in IDDM is located in the COOH-terminal two-thirds of GAD 65 (16, 17) .
Our results indicate that there are two regions of the COOH-terminal two-thirds of GAD 65 that are targeted by IDDM sera. Most IDDM sera bind equal amounts of both GAD 65 (l-442)/GAD 67 (452-594) and GAD 67 (1-451)/GAD 65 (443-585) ( Fig. LA and B) . Some IDDM sera bind more GAD 65 (l-442)/GAD 67 (452-594) than GAD 67 (1^51)/GAD 65 (443-585) (Fig. IB) . Both regions of GAD protein contribute to total GAD binding in IDDM sera. To further narrow the regions targeted by the autoantibodies and to assess the relative contribution of the two regions to total GAD binding in IDDM sera, two additional GAD chimera, GAD 67 (l-230)/GAD 65 (221^42)/GAD 67 (452-594) and GAD 65 (1-195)/GAD 67 (205-441)/GAD 65 (443-585) were created. A chimera containing only amino acids 221-442 of GAD 65 or a chimera containing amino acids 442-585 of GAD 65 was used to inhibit the binding of IDDM sera to full-length GAD 65 . Two patterns of antibody binding in IDDM were observed (Fig. 2) . In the first pattern, preincubation of IDDM sera with either GAD 67 (l-230)/GAD 65 (221-442)/GAD 67 (452-594) or GAD 65 ( 1 -195 )/GAD 67 (205-441)/GAD 65 (443-585) partially inhibited the binding to full-length GAD 65 (Fig. 2) . However, when the sera were preincubated with both chimeric GAD proteins, the binding to full-length GAD 65 was completely inhibited (Fig. 2) . These results indicate the presence of two distinct antibody specificities that target different regions of GAD 65 and contribute to the total GAD binding in IDDM sera. In the second pattern, only the GAD 67 (l-230)/GAD 65 (221-442)/ GAD 67 (452-594) chimera was required to inhibit the binding to full-length GAD 65 (Fig. 2) , indicating that in this IDDM serum, an antibody specificity for amino acids 221-442 is responsible for total GAD binding. If such sera also contain a second GAD specificity that targets amino acids 443-585, this reactivity is present at a much lower titer. Our findings indicate that at least one antibody targets each region. The possibilities that more than one antibody may be responsible for the binding to that region or that more than one epitope within that region may be targeted will require further study.
Identification of amino acids targeted by IDDM sera.
Since GAD 65 between the two isoforms within the two regions of GAD 65 targeted by IDDM sera may identify amino acids responsible for the binding of IDDM sera to GAD 65 , but not GAD 67 . After excluding amino acids that are identical in the GAD 65 and GAD 67 isoforms, the two areas of binding can be narrowed to amino acids 240-435 and amino acids 443-585. The GAD 65 and GAD 67 isoforms are 72 and 64% identical in these two regions, respectively. Since rat GAD 65 (used for these com- parisons) and human GAD 65 are >98% identical in these regions, similar results were found with comparisons of human GAD 65 and human GAD 67 (data not shown). Based on nomenclature suggested by De Camilli and colleagues (14) for GAD epitopes in SMS, we propose to label the epitope contained in amino acids 240^435 IDDM-El and the epitope contained in amino acids 451-570 IDDM-E2. Most of the differences in protein sequence in GAD 65 and GAD 67 in the regions of IDDM-El and IDDM-E2 are single amino acids.
One area of marked difference in the two GAD isoforms in the region of IDDM-E2 (between amino acids 505 and 517 where 10 of 13 amino acids are different) suggests a possible area for future study (Fig. 3) . Additional studies using site-directed mutagenesis should allow for precise identification of the amino acids targeted by the GAD antibodies in IDDM sera.
To assess the frequency of GAD antibodies to these two regions, we measured the binding to IDDM-El and IDDM-E2 of GAD 65 with sera from individuals with new-onset IDDM (n = 12). Most IDDM sera (n = 11 of 12) bound both IDDM-El and IDDM-E2 (Fig. 4) . One IDDM sera bound only IDDM-El.
The two distinct antibody specificities present in IDDM sera may be identical to monoclonal islet cell antibody (MICA) 1 and MICA 3 isolated from a single patient with IDDM by Richter et al. (17) . Comparative studies with these monoclonal antibodies and IDDM sera are important because monoclonal antibodies derived from a single individual with IDDM may not be representative of IDDM sera, and the contribution of a particular monoclonal antibody species to the total GAD autoantibody pool cannot be estimated. The relative amount of a particular GAD autoantibody species in relation to other autoantibody species must use sera from a number of individuals with IDDM. The newly created GAD chimera will be useful in such studies. Implications for IDDM prediction and pathogenesis. GAD antibodies are an important immunological marker for IDDM, but several groups of GAD antibody-positive individuals with a low risk of developing diabetes have now been recognized (11) (12) (13) . Differences in the GAD antibody profile may allow one to distinguish between individuals at high and low risk of developing IDDM. With our identification of regions targeted by IDDM sera, a precise comparison of the GAD antibody profiles should now be possible and will be important in determining the precise role of GAD antibodies as a predictive marker for IDDM. If a specific region is targeted by IDDM sera and not by other GAD antibodypositive sera, then a GAD 65 /GAD 67 chimera could be used to design assays specific for IDDM. In addition, the GAD 65 / GAD 67 chimera will be a useful tool to determine whether differences in the two distinct GAD antibodies identify subsets of IDDM by correlating the presence or absence of a particular GAD antibody species with other aspects of IDDM, such as human leukocyte antigen (HLA) status, temporal relationship to other markers of autoimmunity, and fi-cell function. Possible differences in GAD epitope recognition in IDDM and in individuals with a low incidence of diabetes have led to speculation that differences in the autoimmune repertoire are important in determining whether diabetes develops (13) (14) (15) . Additional studies are now possible to map precisely and compare GAD epitopes in the various GAD antibody-positive groups. If the GAD epitopes are different, this may provide insight into why IDDM develops in some individuals but not in others. If the epitopes are identical, this suggests that either GAD is not the primary antigen targeted in IDDM or that differences in another aspect of the immunity directed at GAD are responsible for the development of IDDM.
